Ringene

Ringene is a biotechnology company based in Suzhou, China, focused on the development of next-generation mRNA therapeutics and vaccines. The company utilizes a proprietary platform for mRNA sequence optimization and lipid nanoparticle (LNP) delivery to target infectious diseases, oncology, and rare genetic disorders. Ringene's lead programs include mRNA vaccines for shingles and respiratory syncytial virus (RSV), which are currently in the IND-enabling or early clinical stages. Founded in 2021 by experienced industry leaders, the company has secured significant backing from prominent venture capital firms to advance its pipeline and manufacturing capabilities. The firm maintains a state-of-the-art R&D facility and a GMP-compliant pilot manufacturing plant to support its internal development and potential future commercialization.